تحري التأثير الخافض لسكر الدم بمركب ميثيل سلفونيل ميثان لدى الأرانب

[1] A. Sapra and P. Bhandari, “Diabetes,” in StatPearls. Treasure Island, FL, USA: StatPearls Publishing, 2023. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK551501/

[2] M. J. Hossain, M. Al-Mamun, and M. R. Islam, “Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused,” Health Science Reports, vol. 7, no. 3, Art. no. e2004, 2024, doi: 10.1002/hsr2.2004.

[3] J. L. Ríos, F. Francini, and G. R. Schinella, “Natural products for the treatment of type 2 diabetes mellitus,” Planta Medica, vol. 81, no. 12/13, pp. 975–994, 2015, doi: 10.1055/s-0035-1546131.

[4] A. Rohilla and S. Ali, “Alloxan induced diabetes: Mechanisms and effects,” International Journal of Research in Pharmaceutical and Biomedical Sciences, vol. 3, no. 2, pp. 819–823, 2012.

[5] S. Lenzen, “The mechanisms of alloxan- and streptozotocin-induced diabetes,” Diabetologia, vol. 51, no. 2, pp. 216–226, 2008, doi: 10.1007/s00125-007-0886-7.

[6] O. M. Ighodaro, A. M. Adeosun, and O. A. Akinloye, “Alloxan-induced diabetes, a common model for evaluating the glycemic-control potential of therapeutic compounds and plants extracts in experimental studies,” Medicina, vol. 53, no. 6, pp. 365–374, 2017, doi: 10.1016/j.medici.2018.02.001.

[7] C. Baker, C. Retzik-Stahr, V. Singh, R. Plomondon, V. Anderson, and N. Rasouli, “Should metformin remain the first-line therapy for treatment of type 2 diabetes?,” Therapeutic Advances in Endocrinology and Metabolism, vol. 12, Art. no. 2042018820980225, 2021, doi: 10.1177/2042018820980225.

[8] G. Rena, D. G. Hardie, and E. R. Pearson, “The mechanisms of action of metformin,” Diabetologia, vol. 60, no. 9, pp. 1577–1585, 2017, doi: 10.1007/s00125-017-4342-z.

[9] N. F. Wiernsperger and C. J. Bailey, “The antihyperglycaemic effect of metformin: Therapeutic and cellular mechanisms,” Drugs, vol. 58, Suppl. 1, pp. 31–39, 1999, doi: 10.2165/00003495-199958001-00009.

[10] V. R. Aroda et al., “Long-term metformin use and vitamin B12 deficiency in the diabetes prevention program outcomes study,” The Journal of Clinical Endocrinology & Metabolism, vol. 101, no. 4, pp. 1754–1761, 2016, doi: 10.1210/jc.2015-3754.

[11] I. Sousa-Lima et al., “Methylsulfonylmethane (MSM), an organosulfur compound, is effective against obesity-induced metabolic disorders in mice,” Metabolism, vol. 65, no. 10, pp. 1508–1521, 2016, doi: 10.1016/j.metabol.2016.07.007.

[12] M. Butawan, R. L. Benjamin, and R. J. Bloomer, “Methylsulfonylmethane: Applications and safety of a novel dietary supplement,” Nutrients, vol. 9, no. 3, Art. no. 290, 2017, doi: 10.3390/nu9030290.

[13] R. K. Velusamy and R. Tamizhselvi, “Protective effect of methylsulfonylmethane in caerulein-induced acute pancreatitis and associated lung injury in mice,” Journal of Pharmacy and Pharmacology, vol. 70, no. 9, pp. 1188–1199, 2018, doi: 10.1111/jphp.12946.

[14] L. Miller et al., “The effect of daily methylsulfonylmethane (MSM) consumption on high-density lipoprotein cholesterol in healthy overweight and obese adults: A randomized controlled trial,” Nutrients, vol. 13, no. 10, Art. no. 3620, 2021, doi: 10.3390/nu13103620.

[15] M. Banasova, K. Valachová, I. Juránek, and L. Soltes, “Aloe vera and methylsulfonylmethane as dietary supplements: Their potential benefits for arthritic patients with diabetic complications,” Journal of Information, Intelligence and Knowledge, vol. 5, no. 1, pp. 51–59, 2013.

[16] S. A. Al Laham, “Methylsulfonylmethane (MSM) as a new target for the treatment of glycerol-induced nephropathy,” Journal of Pharmacy and Nutrition Sciences, vol. 8, no. 3, pp. 137–143, 2018.

[17] J. B. Buse et al., “The primary glucose-lowering effect of metformin resides in the gut, not the circulation: Results from short-term pharmacokinetic and 12-week dose-ranging studies,” Diabetes Care, vol. 39, no. 2, pp. 198–205, 2016, doi: 10.2337/dc15-0488.

[18] K. Hieshima et al., “High frequency of defecation under metformin use may be a potential glucose-lowering factor independent of the dose-dependent effect of metformin in patients with type 2 diabetes mellitus,” Internal Medicine, vol. 64, no. 10, pp. 1485–1495, 2025, doi: 10.2169/internalmedicine.3982-24.

[19] J. Pichette and J. Gagnon, “Implications of hydrogen sulfide in glucose regulation: How H2S can alter glucose homeostasis through metabolic hormones,” Oxidative Medicine and Cellular Longevity, vol. 2016, Art. no. 3285074, 2016, doi: 10.1155/2016/3285074.

[20] L. Zhang, G. Yang, A. Untereiner, Y. Ju, L. Wu, and R. Wang, “Hydrogen sulfide impairs glucose utilization and increases gluconeogenesis in hepatocytes,” Endocrinology, vol. 154, no. 1, pp. 114–126, 2013, doi: 10.1210/en.2012-1658.